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* Additional information regarding ABCs/EIP Network is available at <http://www.cdc.gov/
ncidod/dbmd/abcs> (accessed August 8, 2000).
Preventing Pneumococcal Disease Among Infants
and Young Children
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary
In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate
vaccine (Prevnar,™ marketed by Wyeth Lederle Vaccines) was licensed for use
among infants and young children. CDC’s Advisory Committee on Immunization
Practices (ACIP) recommends that the vaccine be used for all children aged 2–23
months and for children aged 24–59 months who are at increased risk for
pneumococcal disease (e.g., children with sickle cell disease, human
immunodeficiency virus infection, and other immunocompromising or chronic
medical conditions). ACIP also recommends that the vaccine be considered for all
other children aged 24–59 months, with priority given to a) children aged 24–35
months, b) children who are of Alaska Native, American Indian, and African-
American descent, and c) children who attend group day care centers. This report
includes ACIP’s recommended vaccination schedule for infants at ages 2, 4, 6, and
12–15 months. This report also includes a pneumococcal vaccination schedule for
infants and young children who are beginning their vaccination series at an older
age and for those who missed doses. In addition, this report updates earlier
recommendations for use of 23-valent pneumococcal polysaccharide vaccine
among children aged 2 years. Among children aged 24–59 months for whom
polysaccharide vaccine is already recommended, ACIP recommends vaccination
with the new conjugate vaccine followed, 2 months later, by 23-valent
polysaccharide vaccine. Conjugate vaccine has not been studied sufficiently
among older children or adults to make recommendations for its use among
persons aged 5 years. Persons aged 5 years who are at increased risk for
serious pneumococcal disease should continue to receive 23-valent polysaccha-
ride vaccine in accordance with previous ACIP recommendations.
INTRODUCTION
Streptococcus pneumoniae  (pneumococcus) remains a leading cause of serious ill-
ness among young children worldwide and is the most frequent cause of pneumonia,
bacteremia, sinusitis, and acute otitis media (AOM). In the United States, S. pneumoniae
causes approximately 17,000 cases/year of invasive disease among children aged
<5 years, including 700 cases of meningitis and 200 deaths (CDC’s Active Bacterial Core
Surveillance [ABCs]/Emerging Infections Program [EIP] Network, unpublished data,
2000).*
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CDC’s Advisory Committee on Immunization Practices (ACIP) previously recom-
mended 23-valent pneumococcal polysaccharide vaccines for use among children aged
2 years who have high rates of disease, including those with sickle cell disease (SCD),
chronic underlying diseases, human immunodeficiency virus (HIV) infection, or others
who are immunocompromised. The new 7-valent pneumococcal conjugate vaccine
(PCV7;* Prevnar,™ licensed in February 2000 and marketed by Wyeth Lederle Vaccines)
should be a key addition to existing pneumococcal disease prevention measures.
Although the previously licensed 23-valent pneumococcal polysaccharide vaccines
(PPV23; PNU-IMUNE® 23 marketed by Wyeth-Ayerst Laboratories and Pneumovax® 23
by Merck and Company) are effective in preventing invasive pneumococcal disease
among older children and adults, these vaccines do not protect children aged <2 years,
the age group with the highest rate of disease (1–3 ). Furthermore, PPV23 does not
decrease nasopharyngeal carriage, a substantial source of transmission of pneumococci
(4 ). In contrast, conjugate vaccine decreases colonization, and PCV7 prevents pneumo-
coccal disease among children aged 2 years (5–7 ). This report provides ACIP’s recom-
mendations for pneumococcal vaccination of children aged <5 years.
BACKGROUND
Incidence of Invasive Disease Among Children
The highest rates of invasive pneumococcal disease (e.g., bacteremia, meningitis, or
other infection of a normally sterile site) occur among young children, especially those
aged <2 years. In 1998, estimated incidence in the United States of invasive pneumococ-
cal infections among children aged <12 months and 12–23 months were 165 and
203 cases/100,000 population, respectively, with peak incidence occurring among chil-
dren aged 6–11 months (235/100,000). In contrast, incidence among persons of all ages
and among persons aged 65 years were 24 and 61/100,000, respectively (Figure 1) (8 ).
In the United States, the most common manifestation of invasive pneumococcal dis-
ease among young children is bacteremia without a known site of infection, which
accounts for approximately 70% of invasive pneumococcal cases among children aged
<2 years. Only 12%–16% of patients with invasive pneumococcal disease among this
age group have pneumonia (ABCs/EIP Network, unpublished data, 2000). With the suc-
cess of conjugate vaccines in preventing invasive Haemophilus influenzae  type b (Hib)
disease, S. pneumoniae  has become the leading cause of bacterial meningitis in the
United States. Children aged <1 year have the highest incidence of pneumococcal men-
ingitis, which is approximately 10/100,000 population (9 ).
* Abbreviations used in this report are those used by ACIP during development of vaccination
recommendations; they are similar to those already published by the American Academy of
Pediatrics (Source: American Academy of Pediatrics. Policy statement: recommendations
for the prevention of pneumococcal infections, including the use of pneumococcal conjugate
vaccine [Prevnar], pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.
Pediatrics 2000:106:362–6). A new standardized nomenclature system is in development as
part of CDC’s Vaccine Identification Standards Initiative (available at <http://www.cdc.gov/
nip/visi/prototypes/vaxabbrev.htm>; accessed September 15, 2000).
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Occurrence of Noninvasive Syndromes
S. pneumoniae  also contributes substantially to noninvasive respiratory infections
and is the most common bacterial cause of community-acquired pneumonia, AOM, and
sinusitis among young children (10–16 ). In two prospective studies of community-
acquired pneumonia among young children, 17%–28% of cases were diagnosed as pneu-
mococcal (10,11 ). However, these and other studies probably underestimate the actual
proportion of pneumococcal pneumonia cases as a result of low sensitivity of routine
diagnostic testing.
Studies using diagnostic tympanocentesis among children with AOM have found
S. pneumoniae  in 28%–55% of all middle ear aspirates (12–15 ). Otitis media is the most
frequent reason for pediatric office visits in the United States, resulting in >15 million
visits/year (17–19 ). By age 12 months, 62% of children have had at least one episode of
AOM; peak incidence of AOM occurs during ages 6 months–1year (20 ). Although serious
complications are rare, economic costs of otitis media are estimated at >$3.5 billion/year
in the United States (21 ). During 1996, approximately 500,000 tympanostomy tubes
were placed in children’s ears in the United States (22 ). AOM is also the leading reason
for prescribing antibiotics during childhood, and use of antibiotics for treatment of AOM
and sinusitis contributes substantially to increased antimicrobial resistance (23–25 ).
FIGURE 1. Rates of invasive pneumococcal disease by age group — United States, 1998
Source: CDC, Active Bacterial Core Surveillance (ABCs)/Emerging Infectious Program (EIP)
Network, 2000. Available at <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/
spneu98.pdf>. Accessed August 22, 2000.
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Children at Increased Risk for Pneumococcal Infections
Racial and Ethnic Populations
In the United States, higher rates of invasive pneumococcal disease occur among
African-Americans, Alaska Natives, and specific American Indian populations, compared
with whites (Table 1) (26–32 ). Incidence of pneumococcal bacteremia and meningitis
among Alaska Native children aged <5 years ranges from 598 cases/100,000 population
among children aged 6–11 months to 56 cases/100,000 population for children aged 36–
47 months, which is approximately four times that of similarly aged non-Alaska Native/
non-American Indian children (30 ). The highest rates for any ethnic group in the United
States are found among Navajo and Apache populations living on reservations in the
southwestern United States. Incidence among children aged 1–2 years in these popula-
tions is 557–2,396/100,000 (31,32 ). Among children aged <5 years, incidence of invasive
pneumococcal disease among African-American children in the United States is 2–3
times higher than the rate among white children of the same age (8,27,29,33 ). In a case-
control study of risk factors for invasive disease among young children, the association
of race with disease risk was not statistically significant in an analysis that controlled for
socioeconomic status (34 ). However, other studies have reported persistence of
increased risk when controlling for income (27,33,35–37 ). Reasons for increased rates of
disease among Alaska Natives, American Indians, and African-Americans are unclear
but probably multifactorial.
Children with Functional or Anatomic Asplenia
Other children at high risk for invasive pneumococcal disease include patients with
SCD, other sickle hemoglobinopathies (e.g., hemoglobin S-C disease or S-ß-thalassemia),
and those who are otherwise functionally or anatomically asplenic (38–40 ). Although
rates of pneumococcal infection among children with hemoglobin S-C disease are lower
than rates among persons with SCD, rates are higher than among healthy children
(41,42 ). Rates of overall bacterial sepsis in other hemoglobinopathies (e.g., S-ß-
thalassemia) have not been calculated but are estimated to be intermediate between
those for hemoglobin S-C and hemoglobin SS diseases (40 ). High risk for pneumococcal
infections among persons with SCD is thought to be caused by the combination of low
levels of circulating antibodies, splenic dysfunction, and complement deficiency, result-
ing in decreased clearance of encapsulated bacteria from the bloodstream (43,44 ). The
protective effect of pneumococcal polysaccharide vaccine among SCD patients, initially
reported in a study published in 1977, has not been reproduced consistently by subse-
quent prospective or case-control studies (45–49 ). Although use of prophylactic penicil-
lin has reduced the risk for pneumococcal disease, children aged <5 years with SCD still
have increased rates of invasive disease (range: 1,230–1,500/100,000 population), prob-
ably reflecting noncompliance with and failure of penicillin prophylaxis combined with
















TABLE 1. Rates (cases/100,000 population) of invasive pneumococcal disease in selected U.S. pediatric populations — selected years
United Navajo Apache Persons Children
United United States, Alaska American American with with human
States, States, African- Natives, Alaska Indians, Indians, sickle immuno-
all races, whites, Americans, 1986– Natives, 1989– 1983– cell deficiency
Age group 1998* 1998* 1998* 1990† 1986–1997§ 1996¶ 1990** disease†† virus§§
0–5 mos 73.4 60.9 163.5 624¶¶ 276.8 629¶¶ 1,820¶¶ 6,380¶¶ 4,500¶¶
6–11 mos 227.8 178.2 542.2 597.7
12–23 mos 184.2 137.2 440.7 453.0 557 6,340 5,500
24–35 mos 64.7 54.6 116.4 98¶¶ 125.2 73¶¶ 227¶¶ 5,720 9,900
36–47 mos 26.7 23.9 46.1 56.2 900 5,100
48–59 mos 14.3 9.1 20.6 73.2 1,450 2,500
5–9 yrs 5.7 4.8 9.3 23 — — 54 — —
10–19 yrs 2.9 2.5 4.8 5 — — 35 — —
All ages 23.2 19.7 49.7 — — 63 207 1,230 587***
* Source: Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program (EIP) Network, unpublished data, 2000. Additional
information is available at <http://www.cdc.gov/ncidod/dbmd/abcs>. Accessed August 8, 2000.
† Source: Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. Epidemiology of invasive pneumococcal disease
in Alaska, 1986–1990—ethnic differences and opportunities for prevention. J Infect Dis 1994;170:368–76.
§ Source: Butler JC, Bulkow LR, Parks DJ, Parkinson AJ. Epidemiology of pneumococcal bacteremia and meningitis during the first
5 years of life in Alaska: implications for conjugate pneumococcal vaccine use [Abstract 1058]. 39th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999;672.
¶ Source: O’Brien KL, Croll J, Parkinson AJ, Reid R, Santosham M. Active laboratory-based surveillance for invasive Streptococcus
pneumoniae  (pneumococcus) among Navajo people in the American southwest, 1989–1996 [Abstract 1187]. 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999;678.
** Source: Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High incidence rates of invasive pneumococcal
disease in the White Mountain Apache population. Arch Intern Med 1992;152:2277–82.
†† No vaccine or penicillin prophylaxis (Sources: Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI.
Epidemiology of invasive pneumococcal disease in Southern California: implications for the design and conduct of a pneumococcal
conjugate vaccine efficacy trial. J Infect Dis 1996;174:752–9; Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas
County, Texas: results from population-based surveillance in 1995. Clin Infect Dis 1998;26:590–5; and Zarkowsky H, Gallagher D, Gill
FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986;109:579–85).
§§ Source: Mao C, Harper M, McIntosh K, et al. Invasive pneumococcal infections in human immunodeficiency virus-infected children.
J Infect Dis 1996;173:870–6.
¶¶ Average of all age groups indicated by arrows.
*** Source: Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based
surveillance in 1995. Clin Infect Dis 1998;26:590–5.
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HIV-Infected Children
Children infected with HIV have a markedly increased risk for pneumococcal infection
compared with those who are not HIV-infected (50,51 ). In two prospective cohort stud-
ies, HIV-infected children had rates of invasive pneumococcal disease that were 2.8 and
12.6 times the rate among HIV-negative control subjects for children aged <5 and
<3 years, respectively (52,53 ). Incidence of invasive pneumococcal disease is 6.1 cases/
100 patient-years among HIV-infected children through age 7 years (54 ).
Children in Day Care
Out-of-home day care increases the risk for invasive pneumococcal disease and
AOM among children (34,55,56 ). In a study of risk factors for invasive pneumococcal
disease among children in the United States, attendance at a group day care center*
during the preceding 3 months was associated with an approximately 2.3-fold increase
in invasive disease among children aged 12–23 months, and 3.2-fold increased risk among
children aged 24–59 months (34 ). Moreover, in a recent population-based case-control
study, nonelderly adults (i.e., persons aged 18–64 years) who lived in a household that
included children who attended day care were at greater risk for acquiring invasive
pneumococcal infections than adults who did not (multivariate odds ratio [OR] = 3.0) (57 ).
In studies of otitis media resulting from all causes, risk for AOM was higher among
children who attended day care outside the home compared with family day care (58,59 ),
and risk for middle ear effusions increased with exposure to larger numbers of children
in day care settings (60 ). Younger age when starting day care also increases risk for
experiencing recurrent AOM (59 ). Day care attendance is also a risk factor for other
acute upper respiratory tract infections among children aged <5 years (61 ).
Antimicrobial Resistance
Treatment of pneumococcal disease among young children is complicated by emer-
gence of pneumococcal strains resistant to penicillin and other antibiotics (12,62 ). Among
a national sample of invasive pneumococcal isolates, resistance to penicillin (i.e., mini-
mum inhibitory concentration [MIC]  2.0 µg/ml) has increased substantially during the
past decade, from 1.3% in 1992 to 13.6% in 1997 (62,63 ). In certain areas of the United
States, approximately 35% of invasive isolates are penicillin-nonsusceptible (i.e., inter-
mediate susceptibility [MIC = 0.12–1.0 µg/ml] or resistant [MIC  2.0 µg/ml]) (63 ). In one
nasopharyngeal carriage study among children in a rural Kentucky community, 59% of
children attending day care centers carried penicillin-nonsusceptible S. pneumoniae (64 ).
Risk factors associated with infection with penicillin-resistant pneumococci include
younger age, attendance at a day care center, higher socioeconomic status, recent (i.e.,
3 months) antibiotic use, and recurrent AOM (26,34,65,66 ). Recent day care attendance
and recent antibiotic treatment are associated independently with invasive disease as a
result of penicillin-resistant pneumococci (34 ). Penicillin resistance has been associated
with treatment failures in AOM and meningitis (12,67–69 ); these failures could be be-
cause of difficulty in achieving high antimicrobial concentrations in middle ear fluid and
cerebrospinal fluid (CSF) (70 ). Additional research is needed to determine the associa-
tion between penicillin resistance and treatment failure in pneumococcal pneumonia or
bacteremia among children (12,71–73 ).
* Defined in that study as any setting outside the home where a child regularly spends
4 hours/week with 2 unrelated children under adult supervision.
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Pneumococcal Serotypes
The capsule of the Streptococcus pneumoniae  bacterium consists of polysaccha-
rides and constitutes a major virulence factor for the bacterium (74 ). Antibodies directed
against the capsular polysaccharide protect against infection; type-specific antibodies
bind capsular antigens; and opsonization facilitates phagocytosis (75 ). Knowledge of the
distribution of pneumococcal serotypes causing disease is fundamental to evaluating the
potential impact of a pneumococcal vaccine. Currently, 90 serotypes of S. pneumoniae
have been identified on the basis of antigenic differences in their capsular polysaccha-
rides (76 ). The majority of serotypes cause serious disease, yet a relatively limited
number of serotypes cause the majority of invasive pneumococcal infections. The
10 most common serotypes are estimated to account for approximately 62% of invasive
disease worldwide; however, ranking and serotype prevalence differ by age group and
country (77 ). In the United States, the seven most common serotypes isolated from the
blood or CSF of children aged <6 years (i.e., 14, 6B, 19F, 18C, 23F, 4, and 9V) account for
80% of infections and are the serotypes in the licensed PCV7 (Figure 2). These same
seven serotypes, by comparison, account for only 50% of isolates among persons aged
6 years in the United States (78,79 ). Distribution of serotype coverage also differs
among Alaska Natives and American Indians in the United States; the proportion of
vaccine serotypes causing invasive pneumococcal disease among children aged <5 years
is less among Alaska Natives and American Indians than among non-Alaska Natives/
non-American Indians (30,31 ). Types 1 and 5 account for only a limited percentage of
invasive isolates in the United States, but are more common in Western Europe and in
certain developing countries (77,80,81 ). Among children with AOM in rural Kentucky, the
FIGURE 2. Serotype distribution of invasive pneumococcal disease by age group and
vaccine  coverage — United States, 1998
Source: Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program (EIP) Network,
unpublished data, 2000. Additional information is available at <http://www.cdc.gov/
ncidod/dbmd/abcs>. Accessed August 22, 2000.
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seven PCV7 serotypes accounted for 71% of infections among children aged <24 months
(82 ). Among 414 S. pneumoniae  isolates obtained from middle ear fluid cultures among
children with AOM in Finland, 250 (60%) were caused by serotypes contained in PCV7 (83 ).
Antimicrobial resistance is detected most frequently among serotypes included in
PCV7. According to 1998 surveillance data from eight states, the PCV7 serotypes ac-
counted for 80% of 312 penicillin-nonsusceptible isolates (MIC  0.1 µg/ml) collected from
normally sterile sites among children aged <6 years (ABCs/EIP Network, unpublished
data, 1999). A similar serotype distribution of penicillin-nonsusceptible isolates was iden-
tified during a study of nasopharyngeal carriage among 216 children aged <6 years in
Memphis, Tennessee; 78% of resistant isolates were of the same seven serotypes (65 ).
PNEUMOCOCCAL CONJUGATE VACCINE
Advantages of Pneumococcal Conjugate Vaccine:
Immunologic Theory
Bacterial polysaccharides, including those present on the pneumococcal capsule, are
T-independent antigens. T-independent antigens stimulate mature B-lymphocytes but
not T-lymphocytes. This type of antigen induces an immune system response that is
neither long-lasting nor characterized by an anamnestic (i.e., booster) response upon
subsequent challenge with native polysaccharides (84,85 ). Polysaccharide vaccines fail
to elicit a protective immune system response among infants and very young children
because these children respond poorly to T-independent antigens. Although antibody
response to T-dependent antigens is present soon after birth, immune system responses
to T-independent antigens develop during the first years of life. Certain serotypes that
cause the majority of pneumococcal disease among children (i.e., 6A, 14, 19F, and 23F)
remain poorly immunogenic until approximately age 5 years (86 ).
Conjugation of polysaccharides to proteins changes the nature of the
antipolysaccharide response from T-independent to T-dependent. This antigen complex
stimulates a T-helper–cell response, leading to a substantial primary response among
infants and a strong booster response at reexposure (84 ). Success of Hib conjugate
vaccine in reducing by 95% incidence of invasive Hib disease among young children
after the vaccine’s introduction for use among infants in 1990 is one example of the
potential efficacy of bacterial polysaccharide-protein conjugate vaccines. Declines in Hib
disease occurred among children aged <1 year before the vaccine was licensed for use
among this age group (87 ). This herd-immunity effect was consistent with later observa-
tions that Hib conjugate vaccine interrupts transmission by reducing acquisition of car-
riage. Pneumococcal conjugate vaccines, in contrast with polysaccharides, has been
reported to reduce carriage and might lead to population effects beyond direct protection.
Vaccine Composition
The 7-valent pneumococcal conjugate vaccine (Prevnar) includes seven purified cap-
sular polysaccharides of S. pneumoniae, each coupled with a nontoxic variant of diphthe-
ria toxin, CRM197 (CRM, cross-reactive material). The vaccine contains approximately
2 µg each of capsular polysaccharide from serotypes 4, 9V, 14, 19F, and 23F, and oligosac-
charide from 18C, 4 µg of serotype 6B, 20 µg of the carrier protein CRM197, and 0.125 mg
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of aluminum/0.5-ml dose as an aluminum phosphate adjuvant. Prevnar contains no thime-
rosal or other preservative. Serotypes included in PCV7 and potentially cross-reactive
serotypes (i.e., 6A, 9A, 9L, 18B, and 18F) accounted for 86% of bacteremia, 83% of
meningitis, and 65% of AOM among children aged <6 years occurring in the United
States during the period 1978–1994 (79 ).
Immunogenicity
Polysaccharide-protein conjugate vaccine induces type-specific antibodies that bind
to polysaccharide on the surface of bacteria and enhance opsonization, phagocytosis,
and killing of pneumococci. The amount of antibody required to prevent either pneumo-
coccal carriage or disease is unknown. Additionally, quantitative measurement of total
antibody concentration, as measured in the majority of pneumococcal antibody assays,
might not correlate with the level of functional immune system response. Functional
measurements (e.g., opsonophagocytic activity) might be more appropriate than serum
antibody concentrations for evaluating clinically relevant responses to pneumococcal
vaccination (88 ).
Although specific levels of antibody or opsonophagocytic activity that correlate with
protection against pneumococcal disease remain unknown, presence of type-specific
antibody to capsular polysaccharide is associated with protection among adults. Studies
of Hib conjugate vaccine have reported that levels of anticapsular antibody 0.15 µg/ml
are protective against subsequent Hib infection; thus, researchers have hypothesized
that this minimum level might also be protective against pneumococcal disease (89–91 ).
Through measurement of total antibody concentrations, researchers have demonstrated
that pneumococcal conjugate vaccines using several protein carriers are more immuno-
genic than PPV23 among young children (92–98 ).
Immunogenicity Studies Among Healthy Infants and Children
In one study, 212 healthy infants were randomized to receive either PCV7 or an
investigational meningococcal conjugate vaccine at ages 2, 4, 6, and 12–15 months.
Vaccination with PCV7 resulted in substantial increases in serum antibody concentra-
tions to all seven serotypes compared with baseline concentrations. After three doses of
PCV7, from 92% (serotypes 6B and 23F) to 100% (serotype 4) of children had 0.15 µg/ml
of type-specific antibody, and from 51% (serotype 9V) to 90% (serotype 19F) achieved a
level of 1.0 µg/ml against the vaccine serotypes. The fourth dose resulted in an anam-
nestic response to each of the seven serotypes (95 ).
Children with SCD
In a study of children and young adults with SCD, children aged 2 years received
either PPV23 only (n = 12) or PCV7 (two doses, 8 weeks apart) followed by PPV23 8 weeks
later (n = 11) (93 ). When measured 3–6 weeks after administration of PPV23, serum
antibody geometric mean concentrations (GMCs) were higher among the PCV7 plus
PPV23 group than among the PPV23-only group for all of the PCV7 serotypes, reaching
statistical significance for serotypes 14 and 19F. Serum antibody GMCs were similar
between the two groups for serotypes 1 and 15B, two serotypes contained in PPV23 but
not in PCV7, demonstrating that PCV7 did not interfere with the immune system re-
sponse to PPV23. After administration of PPV23, 4 of 11 subjects in the PCV7 plus PPV23
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group and 2 of 11 in the PPV23-only group reported fever. Rates and severity of local
reactions to PPV23 did not differ between the two groups.
In a study of 34 infants aged <24 months with SCD who were vaccinated with PCV7 at
ages 2, 4, and 6 months, GMCs of type-specific immunoglobulin G (IgG) antibodies mea-
sured by enzyme-linked immunoabsorbent assay (ELISA) increased from <0.1 µg/ml at
baseline to >2.0 µg/ml 1 month after the third dose for all seven vaccine serotypes
(97,99 ). Among 27 study participants who remained in the study and who were vacci-
nated with PPV23 at age 24 months, a substantial booster response (GMC > 9.0 µg/ml)
occurred after administration of PPV23 for all serotypes in the PCV7 vaccine. Both serum
opsonic activity and total IgG antibodies were measured for two serotypes (i.e., 6B and
14), and both tests demonstrated substantial increases after the PPV23 booster.
HIV-Infected Children
Data are limited regarding use of PCV7 among HIV-infected children. However, in two
studies using 5-valent formulations of greater antigen content (i.e., 10 µg each of sero-
types 6B, 14, 18C, 19F, and 23F oligosaccharides) and the same carrier protein, conjugate
vaccine was demonstrated to be immunogenic among HIV-infected children (94,100 ). In
a study among 60 children aged 2 years, 5-valent pneumococcal conjugate vaccine was
more immunogenic for all five serotypes than was PPV23 among both HIV-infected (n =
30) and HIV-uninfected (n = 30) children. Among HIV-infected children, 60% demonstrated
a 4-fold rise in IgG level after one dose of conjugate vaccine, compared with 31% after
one dose of PPV23 (P < 0.05) (94 ). Prevaccination CDC HIV classification and CD4 counts
of the HIV-infected children were similar among the conjugate vaccine and PPV23 groups.
In a second study using the same conjugate vaccine among younger children, anti-
body response to three doses of 5-valent pneumococcal conjugate vaccine was com-
pared between 18 HIV-infected children aged 2 years and 33 children without HIV
infection (100 ). The vaccine was found to be immunogenic among both groups. Antibody
levels achieved by the HIV-infected infants and toddlers were higher than those reported
after one dose of 5-valent pneumococcal conjugate vaccine in the study of children aged
2 years discussed previously (94 ). In both studies, no substantial difference in fre-
quency of local or systemic reactions was reported among children who received the
conjugate vaccine compared with control groups.
Alaska Natives and American Indians
Researchers have studied the immunogenicity of a pneumococcal conjugate vaccine
using a different carrier protein among Alaska Native, American Indian, and non-Alaska
Native/non-American Indian infants aged <2 years (101 ). A 7-valent pneumococcal vac-
cine consisting of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F linked with the outer membrane
protein complex of Neisseria meningitidis  was administered to Alaska Native, American
Indian (i.e., Apache and Navajo), and non-Alaska Native/non-American Indian infants
aged 2, 4, and 6 months, with a booster dose at age 15 months. Response after three
primary doses of vaccine was similar among all three groups of infants, except for
serotypes 14 and 23F. However, 1 month after the booster dose, serotype-specific GMCs
increased to all seven serotypes among the three groups of infants when compared with
the pneumococcal IgG GMCs before the booster dose. Although a different conjugate-
carrier protein was used, this study indicated that PCV7 immunogenicity among Alaska
Natives and American Indians will likely be similar to immune system response among
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* Routine vaccinations included diphtheria toxoid-tetanus toxoid-pertussis vaccine;
Haemophilus influenzae  type b conjugate; hepatitis B; oral and inactivated poliovirus;
measles-mumps-rubella; and varicella.
non-Alaska Natives/non-American Indians. Prevnar is under evaluation in an efficacy
study among American Indians, and study results are pending.
Efficacy
Data from a trial using PCV7 provide evidence of the vaccine’s efficacy against inva-
sive pneumococcal disease, as well as its effectiveness against clinical pneumonia and
AOM among healthy children aged <2 years. The results are summarized in the following
section. Other clinical efficacy trials using 7-, 9- and 11-valent pneumococcal conjugate
vaccines are currently being conducted or are planned in the United States, South Africa,
and certain other countries. Outcomes to be measured in these studies include protec-
tive efficacy against overall mortality, pneumonia, invasive disease, AOM, and nasopha-
ryngeal carriage of pneumococci.
Efficacy Trials
In a prospective double-blind study among patients of a health maintenance organi-
zation in northern California, a total of 37,830 healthy children (i.e., without immune
system disorders or serious chronic disease) were randomly assigned to receive either
PCV7 or a control (meningococcal C conjugate) vaccine. Vaccinations were administered
at ages 2, 4, 6, and 12–15 months. Routine, licensed vaccines* were administered con-
currently according to schedule. Initially, diphtheria toxoid-tetanus toxoid whole-cell per-
tussis (DTwP) vaccine was included among the childhood vaccinations; however, during
the study, use of acellular pertussis vaccine became routine. As of March 2000, >50% of
study participants had been followed for 36 months (7 ).
Invasive pneumococcal disease was defined as an acute illness consistent with pneu-
mococcal disease in a child from whom S. pneumoniae  was cultured from a normally
sterile site (e.g., blood or CSF). Cases were identified through active surveillance. At the
time of the primary efficacy analysis in August 1998, PCV7 was 100% efficacious against
vaccine serotypes among children who were either fully vaccinated (i.e., completed the
three-dose primary series) or partially vaccinated (i.e., received 1 doses) (95% confi-
dence interval [CI] = 80.5%–100% and 85.4%–100%, respectively). Additional cases have
been identified since completion of the primary analysis. When all cases of invasive
disease were evaluated during follow-up analysis in April 1999, PCV7 was 97.4% (95% CI
= 82.7%–99.9%) and 93.9% (95% CI = 79.6%–98.5%) efficacious against vaccine sero-
types among children who were fully or partially vaccinated, respectively (Table 2).
Statistically significant serotype-specific protection also was reported for four of the
seven vaccine serotypes (i.e., 19F, 14, 18C, and 23F). The study’s ability to evaluate
efficacy for the remaining three serotypes was limited because too few cases were
caused by these serotypes in either treatment group (7 ). No evidence existed of an
increase in invasive disease caused by nonvaccine serotypes.
To examine effectiveness of PCV7 in preventing pneumonia of any etiology among
the study population as a secondary outcome, investigators reviewed hospital, outpa-
tient, and emergency room records of the children in the study. Monitored outcomes
included clinical diagnoses of pneumonia, clinical pneumonia with abnormal chest
X-rays, and clinical pneumonia with consolidation of 2.5-cm found on chest X-rays.
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TABLE 2. Efficacy of 7-valent pneumococcal conjugate vaccine (PCV7) against invasive
disease among 37,868 infants in a randomized controlled trial — Northern California Kaiser
Permanente, 1995–1999*
Number of cases, Number of cases, Percent efficacy
PCV7 control vaccine† (95% confidence interval)
Primary Efficacy Analysis§
Fully vaccinated,¶ vaccine serotypes 0 17 100.0 (80.5–100)
Intent-to-treat,** vaccine serotypes 0 22 100.0 (85.4–100)
Follow-up Analysis††
Fully vaccinated,¶ vaccine serotypes only 1 39 97.4 (82.7–99.9)
Intent-to-treat,** vaccine serotypes only 3 49 93.9 (79.5–98.5)
All serotypes, including nonvaccine types 6 55 89.1 (73.7–95.8)
* Source: Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187–95.
† Investigational meningococcal group C conjugate vaccine.
§ Through August 1998, when efficacy was declared and trial enrollment was terminated.
¶ Fully vaccinated: received, at a minimum, the three-dose primary series.
** Intent-to-treat analysis includes partially or fully vaccinated children.
†† Through April 1999; continued blinded follow-up of trial subjects.
Among children who received 1 doses of study vaccine (intent-to-treat analysis), use of
PCV7 resulted in 11.4% (95% CI = 1.3%–20.5%) fewer episodes of clinical pneumonia,
regardless of X-ray or culture result. Cases of clinical pneumonia accompanied by an
X-ray with any evidence of an infiltrate were reduced by 33.0% (95% CI = 7.3%–51.5%).
Among children who had clinically diagnosed pneumonia and X-ray evidence of an area
of consolidation of 2.5 cm as read by both a pediatrician and a radiologist, efficacy of
PCV7 was 73.1% (95% CI = 3.0%–88.3%) (102 ).
Effectiveness of PCV7 in preventing health-care visits for AOM from all causes,
including risk for first AOM episode, frequent AOM episodes, and tympanostomy tube
placement, was assessed as a secondary outcome in the Northern California Kaiser
Permanente efficacy trial. Episodes of physician-diagnosed AOM among the study popu-
lation were identified retrospectively through computerized databases of clinic and emer-
gency room encounters. To exclude return visits related to one episode of AOM, a case of
AOM was defined as a visit for otitis media, with no visits for otitis media made during the
previous 21 days, or if the visit had occurred during the previous 21–42 days, the appoint-
ment had been made <3 days in advance. Frequent AOM was defined as 3 episodes
within 6 months or 4 episodes within 1 year.
A substantial reduction in episodes of AOM was found. Vaccine impact was greatest
for frequent otitis and tympanostomy tube placement (Table 3) (7 ). Compared with
children who received control vaccine, children who received PCV7 had 6.4% (95% CI =
3.9%–8.7%) fewer episodes of AOM, 9.1% (95% CI = 4.1%–13.8%) fewer episodes of
frequent AOM (defined as 3 episodes in 6 months or 4 in 1 year), and they underwent
20.3% (95% CI = 3.6%–34.1%) fewer tympanostomy tube placements (Table 3). Among a
subset of study children with spontaneously ruptured tympanic membranes,
S. pneumoniae  was cultured from the draining ears of 6 children vaccinated with PCV7
and 17 children who received the control vaccine (vaccine efficacy was 65% for AOM
caused by vaccine-serotype pneumococci [P = 0.035]).
The ability of PCV7 to protect children against AOM was also evaluated in an efficacy
trial conducted in Finland (103 ). Children (N = 1,662) were randomized to receive either
PCV7 or hepatitis B (control) vaccine at ages 2, 4, 6, and 12 months. Outcomes measured
included AOM with concurrent myringotomy to establish bacterial diagnosis. Investiga-
tors reported 2,596 AOM episodes during the follow-up period in perprotocol analysis. Of
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TABLE 3. Effectiveness of 7-valent pneumococcal conjugate vaccine (PCV7) against
clinically diagnosed acute otitis media among 37,868 infants in a randomized controlled trial
— Northern California Kaiser Permanente, 1995–1999*
Estimated reduction (%) Estimated reduction (%)
(95% confidence interval) (95% confidence interval)
Outcome measured Analysis of fully vaccinated children† Intent-to-treat analysis§
All otitis media episodes 7.0 (4.1–9.7) 6.4  (3.9– 8.7)
Frequent otitis media
(i.e., 3 episodes in 6 mos or 4 episodes in 1 yr) 9.3 (3.0–15.1) 9.1 (4.1–13.8)
Frequent otitis media
(i.e., 4 episodes in 6 mos or 5 in 1 yr) 11.9 (1.6–21.1) 10.0 (2.4–17.0)
Frequent otitis media
(i.e., 5 episodes in 6 mos or 6 in 1 yr) 22.8 (6.7–36.2) 12.3  (0–23.2)
Ventilatory tube placement 20.1 (1.5–35.2) 20.3 (3.6–34.1)
* Source: Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187–95.
† Fully vaccinated: subjects received, at a minimun, the three-dose primary series.
§ Intent-to-treat analysis includes fully and partially vaccinated children (i.e., subjects received one, two, three, or
four doses of PCV7).
these, 357 episodes were caused by vaccine-serotype pneumococci. A total of 107 epi-
sodes occurred among the PCV7 group, and 250 among the control group, for an esti-
mated efficacy of 57% (95% CI = 44%–67%) against culture-confirmed AOM caused by
vaccine serotypes. The estimated percent efficacy was lower for outcomes that included
nonvaccine pneumococcal serotypes or other pathogens causing AOM. For prevention
of AOM caused by pneumococci of any serotype, efficacy was estimated to be 34% (95%
CI = 21%–45%), and efficacy against AOM irrespective of etiology was 6% (95% CI = -4%–16%)
(83 ). Further analysis revealed an efficacy against vaccine-related serotypes (i.e., 6A,
9N, 18B, 19A, and 23A) of 51% (95% CI = 27%–67%). An increase of 33% in the rate of
AOM episodes caused by nonvaccine serotypes occurred among the group who
received PCV7 compared with the control group. However, in spite of the increase in
disease caused by nonvaccine serotypes, the net effect regarding pneumococcal AOM
was a reduction of 34%.
Effect on Antimicrobial Use
Prevention of pneumococcal infections among young children after widespread use
of PCV7 might result in decreased use of antibiotics, as reported in the Northern Califor-
nia Kaiser Permanente vaccine efficacy trial where a 5.3% reduction was reported among
the group of children who received PCV7 (104 ). A reduction in antibiotic use might slow
or reverse the trend of increasing prevalence of antimicrobial resistance among pneu-
mococci.
Other Studies of Vaccine Impact
Hib conjugate vaccines reduce acquisition of nasopharyngeal carriage of the bacte-
rium among infants and children, an effect that is thought to contribute to the success of
Hib vaccination programs by providing herd immunity (105 ). A 40% and 50% reduction
of vaccine-serotype S. pneumoniae  carriage has been reported in studies of a 9-valent
CRM197 pneumococcal conjugate vaccine conducted in Israel and South Africa, respec-
tively (5,6 ). In both studies, vaccination resulted in a reduction in nasopharyngeal car-
riage of vaccine-type pneumococci and a simultaneous increase in detection of carriage
of pneumococci of nonvaccine serotypes. Whether this represents true replacement or
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unmasking of serotypes that were also colonizing the nasopharynx is unknown. Addi-
tional information regarding the impact of PCV7 on nasopharyngeal carriage is expected
from a future efficacy trial among Navajo and Apache populations.
In a double-blind, randomized study of a 9-valent pneumococcal conjugate vaccine
containing the CRM197 carrier among healthy toddlers attending day care centers in
Israel, conjugate vaccine or control (meningococcal C conjugate) vaccine was adminis-
tered to children in two age groups, 12–17 months (two doses) and 18–35 months (one
dose). Primary outcomes were carriage rates of vaccine serotype- and penicillin-resis-
tant pneumococci. After 21 months of follow-up, carriage rates of vaccine-serotype pneu-
mococci were substantially lower among toddlers who were vaccinated with 9-valent
pneumococcal conjugate vaccine compared with the control group. For both vaccine-
serotype and penicillin-resistant S. pneumoniae, differences in carriage persisted for
children aged <36 months and those 36 months, although the difference was greatest
for children aged <36 months. The study also reported herd immunity within families;
siblings of 9-valent pneumococcal conjugate vaccine recipients were substantially less
likely to carry antibiotic-resistant pneumococci compared with siblings of control-
vaccine recipients (106 ).
Duration of Protection
Duration of protection after vaccination with PCV7 is unknown. However, immuno-
logic memory does occur. Among infants aged 20 months who received primary vacci-
nation with two or three doses of PCV7, administration of PPV23 18 months later resulted
in a booster response. A similar response was elicited among children aged
2–3 years when administered PPV23 20 months after a bivalent (i.e., 6A plus 23F)
CRM197 conjugate vaccine (92,96 ). Additional studies of PCV7 with longer follow-up
periods are needed. Evaluation of duration of protection will be critical for older children
at high risk for disease (e.g., those with SCD or HIV infection).
Cost-Benefit Analysis
Costs and benefits of a routine PCV7 program for healthy U.S. infants and children
were evaluated in a study using current estimates of pneumococcal disease burden (i.e.,
meningitis, bacteremia, pneumonia, and AOM episodes), clinical outcomes, vaccine effi-
cacy, and health-care costs (107 ). Sources of clinical outcomes and costs included pub-
lished and unpublished data, expert consensus, and computerized databases from Kaiser
Permanente of Northern California. For each annual U.S. birth cohort, routine PCV7
vaccination is estimated to prevent approximately 12,000 (78% of potential) cases of
pneumococcal meningitis and bacteremia; 53,000 (69% of potential) pneumococcal pneu-
monia cases; and >1 million (8% of potential) episodes of clinically diagnosed otitis me-
dia. Vaccination of healthy infants would result in net savings to society if vaccine costs
were $46/dose. Net savings to health insurers would result if the vaccine costs were
$18/dose. A program in which one dose of vaccine was administered to children aged
24–59 months to bring them up-to-date with their vaccinations would result in societal
cost savings at a vaccine price of $80 for children aged 24–35 months and $50 for
those aged 48–59 months. From the health-care–payer perspective, savings would
result if vaccine costs were $40 and $20 when administered to children aged 24–35
months and 48–59 months, respectively. Results of this study demonstrate that cost-
effectiveness of vaccination of infants and toddlers is most influenced by vaccine price,
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* Initially all children in the study received the whole-cell pertussis vaccine and oral poliovirus
vaccine; however, after changes in vaccine recommendations midway through the study,
participants began receiving the diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine
and the inactivated poliovirus vaccine.
especially among children aged 24 months. In a recent reanalysis of cost-effectiveness
of PCV7 using additional and updated information (including newly available safety data,
national costs, and rates of tympanostomy tube placement), the same investigators
found that break-even costs for vaccination of infants from societal and health-care–
payer perspective were $40 and $17, respectively (108 ).
Vaccine Safety
Safety of Administration of PCV7 Series Among Infants
Rates and types of adverse events associated with PCV7 administered at ages 2, 4, 6,
and 12–15 months are acceptable when compared with the demonstrated benefits of
vaccination. In the Northern California Kaiser Permanente efficacy trial, rates of adverse
events were compared between children who received PCV7 and those who received
the control vaccine (investigational group C meningococcal conjugate). Routine child-
hood vaccines were administered concurrently with PCV7 and control vaccines.* To
assess vaccine safety, information regarding local and systemic reactions was collected
at 48–72 hours and 14 days after each dose. Using telephone interviews, investigators
collected adverse-event histories for two subsets of the study population — initially a
group receiving DTwP (N = 6,000) and later a group receiving diphtheria toxoid-tetanus
toxoid acellular pertussis (DTaP) vaccine (N = 1,500). Frequency of uncommon events
requiring medical attention after vaccination was evaluated for the entire study cohort
and included emergency room and outpatient clinic visits occurring 30 days and hospi-
talizations occurring 60 days after receiving the study vaccines.
PCV7 vaccination resulted in less frequent local reactions than DTwP vaccine, but
more frequent local reactions than DTaP vaccine and the control vaccine. Except for
erythema, no pattern of increasing local reactogenicity with subsequent doses of PCV7
was reported (Table 4).
Fever 100.4 F (38 C) 48 hours after vaccination was more common among chil-
dren who received PCV7 concomitantly with DTaP vaccine and other recommended
vaccines than among those who received the control vaccine. This difference was statis-
tically significant after each dose of vaccine in the primary series but not the fourth dose
(Table 5). Rates of fever >102.2 F (>39 C) were substantially greater among those who
received PCV7 after dose two of the primary series (i.e., 2.5% versus 0.8%).
Febrile seizures after vaccination were slightly more common in the PCV7 group;
however, the majority of events occurred when whole-cell pertussis vaccine was admin-
istered concurrently with PCV7. Using hospitalizations, emergency room visits, and data
from all other sources, seizures occurring 3 days after vaccination were reported for
four children who received control vaccine and eight who received PCV7. Of the eight
PCV7 recipients who had a seizure, seven had received concurrent DTwP vaccine. Two

















TABLE 4. Percentage of subjects reporting local reactions 2 days after vaccination of infants with 7-valent pneumococcal conjugate
vaccine (PCV7) and diphtheria toxoid-tetanus toxoid-acellular pertussis (DTaP) vaccine at ages 2, 4, 6, and 12–15 months*
Dose 1 Dose 2 Dose 3 Dose 4
PCV7 site DtaP site PCV7 site DTaP site PCV7 site DTaP site PCV7 site DTaP† site
Reaction (N = 693) (N = 693) (N = 526) (N = 526) (N = 422) (N = 422) (N = 165) (N = 165)
Erythema
Any 10.0 6.7§ 11.6 10.5 13.8 11.4 10.9 3.6§
>2.4 cm 1.3 0.4§ 0.6 0.6 1.4 1.0 3.6 0.6
Induration
Any 9.8 6.6§ 12.0 10.5 10.4 10.4 12.1 5.5§
>2.4 cm 1.6 0.9 1.3 1.7 2.4 1.9 5.5 1.8
Tenderness
Any 17.9 16.0 19.4 17.3 14.7 13.1 23.3 18.4
Interfered with limb movement 3.1 1.8§ 4.1 3.3 2.9 1.9 9.2 8.0
*Source: Food and Drug Administration. Product approval information—licensing action. Hyattsville, MD: US Department of Health and Human Services, Food and Drug
Administration, Center for Biologics Evaluation and Research, 2000. Available at <http://www.fda.gov/cber/products/pneuled021700.htm>. Accessed August 9, 2000.
† Subjects might have received diphtheria toxoid-tetanus toxoid-whole-cell pertussis (DTwP) vaccine or a mixed DTwP/DTaP vaccine regimen for the primary series;
therefore, this column represents the fourth dose of a pertussis vaccine, but not necessarily a fourth dose of DTaP.
§ P < 0.05 when PCV7 site is compared with DTaP site using the sign test.
Vol. 49 / No. RR-9 MMWR 17
TABLE 5. Occurrence of fever 48 hours after vaccination — infants receiving 7-valent
pneumococcal conjugate vaccine (PCV7) or control (i.e., meningococcal C conjugate)
vaccine*†
PCV7 Control Vaccine
Reaction % N % N P-value
Fever 100.4 F (38 C)
Dose 1 15.1 709 9.4 710 0.001
Dose 2 23.9 556 10.9 507 0.001
Dose 3 19.1 461 11.8 414 0.003
Dose 4 21.0 224 17.0 230 0.274
Fever >102.2 F (>39 C)
Dose 1 0.9 709 0.3 710 0.178
Dose 2 2.5 556 0.8 507 0.029
Dose 3 1.7 461 0.7 414 0.180
Dose 4 1.3 224 1.7 230 >0.999
* Administered concomitantly with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine and other recom-
mended childhood vaccines.
† Source: Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187–95.
vaccination, one in each of the PCV7 and control-vaccine groups (109 ). The seizure rate
3 days after vaccination with PCV7 and concurrent vaccinations was approximately 1/
7,000 doses, below historic rates after whole-cell pertussis vaccinations (109,110 ).
As of April 20, 1999, a total of 32 children who were originally enrolled in the study
had died (109 ); however, none of the deaths were reported by investigators to be related
to the vaccine. A total of 12 cases of sudden infant death syndrome (SIDS) were
observed among the study cohort 1 year after vaccination, 4 among the PCV7 group
(0.2 cases/1,000 children) and 8 among the control group (0.4 cases/1,000 children).
These rates are less than expected historically; 0.5 cases/1,000 children were observed
in California in 1996 and 1997. One death attributable to SIDS occurred within the first
week of vaccination in a child who received PCV7 concurrently with other vaccines. In an
age- and season-adjusted analysis based on California SIDS data, 1.06 cases would have
been expected 1 week after vaccination (7 ).
Safety of Administration of PCV7 Among Older Children
Safety data are available from four immunogenicity studies of PCV7 among older
infants and children (109 ). Approximately 900 doses of PCV7 were administered to
560 children aged 7 months–9 years following the recommended schedule for vaccina-
tion administration for children who are beyond the age of the infant schedule. Compari-
sons across the studies demonstrate that, generally, frequency of local reactions was
higher among older children than among children vaccinated at age <1 year. Frequency
of fever of 100.4 F (38 C) after one dose of PCV7 ranged from 6.8% to 36.7%. No
distinct, age-related patterns of systemic reactions was evident. Fussiness was the most
commonly observed systemic reaction (Tables 6,7).
Safety of Administration of PCV7 After PPV23
Minimal safety data are available regarding the sequence of PPV23 followed by PCV7.

















TABLE 6. Percentage of subjects reporting local reactions 3 days after 7-valent pneumococcal conjugate (PCV7) vaccination —
infants and children aged 7 months–9 years*
Age at first vaccination
7–11 12–23 24–35 36–59 5–9
mos mos mos mos years
Study number 118-12 118-16 118-9 118-18 118-18 118-18 118-18
Dose number 1 2 3 1 2 3 1 1 2 1 1 1
Number of Subjects 54 51 24 81 76 50 60 114 117 46 48 49
Reaction
Erythema
Any 16.7 11.8 20.8 7.4 7.9 14.0 48.3 10.5 9.4 6.5 29.2 24.2
>2.4 cm† 1.9 0 0 0 0 0 6.7 1.8 1.7 0 8.3 7.1
Induration
Any 16.7 11.8 8.3 7.4 3.9 10.0 48.3 8.8 6.0 10.9 22.9 25.5
>2.4 cm† 3.7 0 0 0 0 0 3.3 0.9 0.9 2.2 6.3 9.3
Tenderness
Any 13.0 11.8 12.5 8.6 10.5 12 46.7 25.7 26.5 41.3 58.3 82.8
Interfered with
limb movement 1.9 2.0 4.2 1.2 1.3 0 3.3 6.2 8.5 13.0 20.8 39.4
*Source: Adapted from Food and Drug Administration. Product approval information—licensing action. Hyattsville, MD: US Department of Health and Human Services,
Food and Drug Administration, Center for Biologics Evaluation and Research, 2000. Available at <http://www.fda.gov/cber/products/pneuled021700.htm>. Accessed
August 9, 2000.

















TABLE 7. Percentage of subjects reporting systemic reactions3 days after 7-valent pneumococcal conjugate (PCV7) vaccination—
infants and children aged 7 months–9 years*
Age at first vaccination
7–11 12–23 24–35 36–59 5–9
mos mos mos mos yrs
Study number 118-12 118-16 118-9 118-18 118-18 118-18 118-18
Dose number 1 2 3 1 2 3 1 1 2 1 1 1
Number of Subjects 54 51 24 85 80 50 60 120 117 47 52 100
Reaction
Fever
100.4 F (38 C) 20.8 21.6 25.0 17.6 18.8 22.0 36.7 11.7 6.8 14.9 11.5 7.0
>102.2 F (>39 C) 1.9 5.9 0 1.6 3.9 2.6 0 4.4 0 4.2 2.3 1.2
Fussiness 29.6 39.2 16.7 54.1 41.3 38.0 40.0 37.5 36.8 46.8 34.6 29.3
Drowsiness 11.1 17.6 16.7 24.7 16.3 14.0 13.3 18.3 11.1 12.8 17.3 11.0
Decreased Appetite 9.3 15.7 0 15.3 15.0 30.0 25.0 20.8 16.2 23.4 11.5 9.0
*Source: Adapted from Food and Drug Administration. Product approval information—licensing action. Hyattsville, MD: US Department of Health and Human Services,
Food and Drug Administration, Center for Biologics Evaluation and Research, 2000. Available at <http://www.fda.gov/cber/products/pneuled021700.htm>. Accessed
August 9, 2000.
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participants had already received one dose of PPV23 3–15 years previously (persons
who had received PPV23 within the previous 2 years were excluded). Of these 16 SCD
patients, 9 who had received two doses of PCV7 followed by one dose of PPV23 8 weeks
later were compared with 7 who had received one dose of PPV23. No severe reactions
were reported; local reactions were similar between the two groups (93 ).
Safety of Administration of PPV23 After PCV7
Five studies have been completed in which 152 infants, children, or young adults
received 1 doses of 2-, 5-, or 7-valent pneumococcal conjugate vaccine conjugated to
CRM197 followed by a dose of PPV23. Populations studied included healthy infants and
children (92,96 ), HIV-infected children and young adults (94 ), and infants and children
with SCD (93,99 ). PPV23 was administered 6 weeks–20 months after pneumococcal
conjugate vaccine. Adverse events were described in three of the five studies. No seri-
ous adverse events were identified after the dose of PPV23. No increase in adverse
events was reported among HIV-infected persons who received 5-valent pneumococcal
conjugate vaccine followed by PPV23 as compared with those who received PPV23 alone
(94 ). Among children with SCD who received either PCV7 followed by PPV23 or PPV23
alone, fever occurred among 4 of 11 and 2 of 11 children, respectively. Local reactions
did not differ between the two groups (93 ).
PPV23 Revaccination
No published studies have been designed specifically to examine adverse events
among children who were administered a second dose of PPV23 after an earlier dose of
PPV23. However, in the previously described study (93 ) in which young children and
adults with SCD were vaccinated with either PCV7 and PPV23 consecutively or PPV23
alone, 16 of 23 enrolled patients had been vaccinated with one dose of PPV23 3–15 years
earlier. All patients were randomized to receive either one dose of PPV23 or two doses of
PCV7 followed by a booster dose of PPV23 8 weeks later. No severe reactions were
reported after the second dose of PPV23.
Vaccine Administration
PCV7 is administered intramuscularly as a 0.5-ml dose. PCV7 is licensed for use
among infants aged 6 weeks. PCV7 can be administered at the same time as other
routine childhood vaccinations in a separate syringe at a separate injection site. In clinical
studies of PCV7, when routine childhood vaccinations were administered simultaneously
with PCV7 vaccine but at different sites, suppression of Hib response occurred after the
fourth dose. However, >97% of children achieved antibody titers 1 µg/ml. Additionally, a
limited decrease in antibody response to poliovirus Type 1 occurred; however, clinical
significance of these decreased responses is uncertain (109,111 ).
Conjugate vaccines containing diphtheria toxoid or protein as carriers (e.g., CRM197)
should not be considered immunizing agents against diphtheria. Thus, no change in the
vaccination schedule for DTaP vaccine is currently recommended. Simultaneous admin-
istration of PCV7 with other vaccines at the 2-, 4-, and 6-month visits might necessitate
five injections at each visit. Physicians might consider potential approaches to decreas-
ing the number of simultaneous injections that are needed. One approach is to administer
the first two doses of hepatitis B vaccine at birth and age 1 month. Alternatively, a Hib-
hepatitis B combination product is available for use at ages 2, 4, and 12–15 months. An
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* VAERS forms can be obtained by calling (800) 822-7967, and additional information is
available at <http://www.vaers.org> (accessed July 31, 2000).
† A Strong evidence, including results of efficacy studies, supports vaccine use.
B Moderate evidence, including immunogenicity data but not efficacy data, supports vaccine
use.
C No efficacy or immunogenicity studies are available regarding this population, but
protection is anticipated on the basis of such studies among other groups; vaccination is
supported by respected authorities.
option to decrease the number of simultaneous injections when the fourth dose is admin-
istered would be to divide needed injections between visits at ages 12 months and 15 or
18 months. Combination vaccine products currently being evaluated by manufacturers
might further decrease the need for multiple injections.
Precautions and Contraindications
Vaccination with PCV7 is contraindicated among persons known to have a hypersen-
sitivity to any component of the vaccine. Health-care providers can choose to delay
vaccination of children with moderate or severe illness until the child has recovered,
although minor illnesses (e.g., mild upper-respiratory infection with or without low-grade
fever) are not contraindications to vaccination. Any adverse event suspected to be asso-
ciated with PCV7 vaccination should be reported to the Vaccine Adverse Events Report-
ing System (VAERS).* Concurrent administration of PCV7 and PPV23 is not recommended
because safety and efficacy of concurrent vaccination has not been studied.
RECOMMENDATIONS FOR USE OF PCV7
Children for Whom PCV7 Is Recommended
Children Aged 23 Months
All children aged 23 months should be vaccinated with PCV7 (Table 8). Infant vacci-
nation provides the earliest possible protection, and children aged 23 months have the
highest rates of pneumococcal infection. PCV7 is safe and highly efficacious in preventing
invasive disease, and it is effective in preventing a portion of AOM cases and pneumonia
among healthy infants and young children (Strength of evidence: children aged 2–6 months,
A;†children aged 7–23 months, B) (Table 9).
Vaccination Schedule. Infants receiving their first dose at age 6 months should re-
ceive three doses of PCV7 at intervals of approximately 2 months, followed by a fourth
dose at age 12–15 months (Table 10). Newborns should begin the schedule at age
2 months, although PCV7 can be administered as young as age 6 weeks. Prematurely
born infants (i.e., <37 weeks gestation) should receive PCV7 at the recommended
chronologic age concurrent with other routine vaccinations. For infants with prolonged
nursery stays, initiation of vaccination should begin during discharge planning. Children
aged 7 months not previously vaccinated should also be vaccinated according to the
recommended schedule (Table 10). The proposed vaccination schedule is the same for
all children aged 23 months, regardless of the presence of underlying medical condi-
tions (e.g., children with HIV infection, SCD or other asplenia, chronic disease, or who are
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TABLE 8. Summary of recommendations for use of 7-valent pneumococcal conjugate
vaccine (PCV7) among infants and children
Children for whom PCV7 is recommended
All children aged 23 mos
Children aged 24–59 mos with the following conditions:
• Sickle cell disease and other sickle cell hemoglobinopathies, congenital or acquired
asplenia, or splenic dysfunction
• Infection with human immunodeficiency virus
• Immunocompromising conditions, including
— Congenital immunodeficiencies: B- (humoral) or T-lymphocyte deficiency;
complement deficiencies, particularly c1, c2, c3, and c4 deficiency; and
phagocytic disorders, excluding chronic granulomatous disease
— Renal failure and nephrotic syndrome
— Diseases associated with immunosuppressive therapy or radiation therapy,
including malignant neoplasms, leukemias, lymphomas, and Hodgkin’s
disease; or solid organ transplantation
• Chronic illness, including
— Chronic cardiac disease, particularly cyanotic congenital heart disease and cardiac
failure
— Chronic pulmonary disease, excluding asthma unless on high dose corticosteroid
therapy
— Cerebrospinal fluid leaks
— Diabetes mellitus
Children for whom PCV7 should be considered
All children aged 24–59 mos, with priority given to
• Children aged 24–35 mos
• Children of Alaska Native or American Indian descent
• Children of African-American descent
• Children who attend group day care centers*
* Defined as a setting outside the home where a child regularly spends 4 hours per week with
2 unrelated children under adult supervision.
TABLE 9. Strength of evidence supporting use of 7-valent pneumococcal conjugate vaccine
(PCV7) among previously unvaccinated infants and children aged 0–59 months
Population Age at vaccination (mos) Strength of evidence*
Healthy children 2–6 A
7–59 B
Children with sickle cell disease or
who are otherwise asplenic and children
with human immunodeficiency virus infection 0–59 B
Children with chronic illness or
who are immunocompromised† 0–59 C
* A Strong evidence, including results of efficacy studies, supports vaccine use.
B Moderate evidence, including immunogenicity data but not efficacy data, supports vaccine use.
C No efficacy or immunogenicity studies are available regarding this population, but protection is anticipated on
the basis of such studies among other groups; vaccination is supported by respected authorities.
† See Table 8.
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otherwise immunocompromised). Interruption of the vaccination schedule does not
require reinstitution of the entire series or the addition of extra doses (Table 11).
Children Aged 24–59 Months Who Are at High Risk
for Pneumococcal Infection
Children aged 24–59 months should receive PCV7 vaccination if they are at high risk
for pneumococcal infection caused by an underlying medical condition (Table 8). This
recommendation applies to the following groups:
• children with SCD and other sickle cell hemoglobinopathies, including hemoglobin
SS, hemoglobin S-C, or hemoglobin S-ß-thalassemia, or children who are
functionally or anatomically asplenic;
• children with HIV infection;
• children who have chronic disease, including chronic cardiac and pulmonary
disease (excluding asthma), diabetes mellitus, or CSF leak; and
• children with immunocompromising conditions, including a) malignancies (e.g.,
leukemia, lymphoma, Hodgkin’s disease); b) chronic renal failure or nephrotic
syndrome; c) those children receiving immunosuppressive chemotherapy,
including long-term systemic corticosteroids; and d) those children who have
received a solid organ transplant.*
Immunogenicity and safety studies have been conducted using PCV7 among children
with SCD (93,97,99 ) and a 5-valent conjugate vaccine among children with HIV infection
(94,100 ) (Strength of evidence: B). The efficacy of PCV7 among children with chronic
disease or who are immunocompromised has not been evaluated, but effectiveness is
anticipated on the basis of studies conducted in other groups (Strength of evidence: C).
Vaccination Schedule. For children aged 24–59 months with underlying medical con-
ditions (Table 8), ACIP recommends two doses of PCV7, administered 2 months apart,
followed by one dose of PPV23 administered 2 months after the second dose of PCV7
(Tables 10,12). The recommendation for two PCV7 doses is based on results of an immu-
nogenicity study conducted among SCD patients. That study reported that a
nonstatistically significant antibody response to serotype 6B after one dose of PCV7
increased statistically significantly after a second dose of PCV7 (93 ). Serotype 6B is one
of the most common pneumococcal serotypes colonizing or causing invasive disease
among SCD patients and healthy children (47,112–114 ).
* This recommendation excludes children who have received a bone marrow transplant
(BMT). Children who undergo BMT have impaired humoral immune system responses for
months or years after the procedure and are at increased risk for serious pneumococcal
infection. Because studies among this population are not complete, ACIP is currently unable
to make recommendations regarding use of PCV7 among BMT patients. PCV7 might produce
superior antibody responses compared with PPV23 among BMT patients. However, pending
results of studies of PCV7 among BMT patients, health-care providers should vaccinate this
population with PPV23 vaccine at 12 and 24 months after BMT, as recommended by an
expert panel (Source: CDC. Guidelines for preventing opportunistic infections among
hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious
Disease Society of America, and the American Society of Blood and Marrow Transplantation.
MMWR 2000;in press).
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TABLE 10. Recommended schedule for use of 7-valent pneumococcal conjugate vaccine
(PCV7) among previously unvaccinated infants and children by age at time of first vaccination
Age at first dose (mos) Primary series Additional dose
2–6 3 doses, 2 mos apart* 1 dose at 12–15 mos†
7–11 2 doses, 2 mos apart* 1 dose at 12–15 mos†
12–23 2 doses, 2 mos apart§ —
24–59
Healthy children 1 dose —
Children with sickle cell disease, asplenia,
human immunodeficiency virus infection,
chronic illness, or immunocompromising
condition¶ 2 doses, 2 mos apart —
* For children vaccinated at age <1 year, minimum interval between doses is 4 weeks.
† The additional dose should be administered 8 weeks after the primary series has been completed.
§ Minimum interval between doses is 8 weeks.
¶ Recommendations do not include children who have undergone a bone marrow transplantation (see Table 8).
TABLE 11. Recommendations for use of 7-valent pneumococcal conjugate vaccine (PCV7)
among children with a lapse in vaccine administration
Age at Previous PCV7 Recommended
examination (mos) vaccination history regimen
7–11 1 dose 1 dose of PCV7 at 7–11 mos, with a second dose
 2 mos later, at 12–15 mos
2 doses Same regimen
12–23 1 dose before age 12 mos 2 doses of PCV7 2 mos apart
2 doses before age 12 mos 1 dose of PCV7 2 mos after the most recent dose
24–59 Any incomplete schedule 1 dose of PCV7*
* Children with certain chronic diseases or immunosuppressing conditions should receive two doses 2 months
apart (see Table 8).
Penicillin prophylaxis should be continued for children with SCD to age 5 years,
regardless of vaccination with PCV7. Protective efficacy of PCV7 for children with SCD
has not been studied, and the vaccine does not protect against all serotypes causing
disease. However, penicillin prophylaxis substantially reduces the risk for invasive pneu-
mococcal infections among SCD patients (112 ).
Other Children Who Might Benefit from Vaccination with PCV7
ACIP recommends that health-care providers consider PCV7 vaccination for all other
children aged 24–59 months, with priority given to the following populations:
• children aged 24–35 months;
• children of Alaska Native or American Indian descent;
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TABLE 12. Schedule for vaccination using 23-valent polysaccharide vaccine (PPV23)
for children aged 2 years who have previously received the 7-valent conjugate vaccine
(PCV7)
Population Schedule for PPV23 Revaccination with PPV23*
Healthy children None† No
Children with sickle cell disease 1 dose of PPV23 administered at age 2 Yes¶
or anatomic or functional asplenia; yrs and 2 mos after last dose
immunocompromised;§ or who are of PCV7
infected with human immunodeficiency virus
Persons with chronic illness§ 1 dose of PPV23 administered at age 2 Not recommended
yrs and 2 mos after last dose
of PCV7
* Recommendations for revaccination are adapted from CDC. Prevention of pneumococcal disease: recommendations
of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-8):12.
† Health-care providers of Alaska Natives and American Indians should consider whether these children would
benefit by the additional coverage provided by the expanded serotypes in PPV23 (see recommendations regarding
Alaska Natives and American Indians).
§ See Table 8.
¶ Regardless of when administered, a second dose of PPV23 should not be administered <3 years after the previous
PPV23 dose. If the patient is aged >10 years, one revaccination should be administered 5 years after the previous
PPV23 dose. If the patient is aged 10 years, one revaccination 3–5 years after previous dose should be
considered (Sources: CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 1997;46[No. RR-8]:1–24; and American Academy of Pediatrics.
Pneumococcal infections. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases.
25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:459).
* Defined as any setting outside the home where a child regularly spends 4 hours/week with
2 unrelated children under adult supervision.
• children of African-American descent;
• children who attend group day care centers;*
This recommendation is made on the basis of the moderate risk for pneumococcal
disease, including antibiotic-resistant infections, among these populations and on poten-
tial cost-benefit. Data regarding efficacy and immunogenicity of PCV7 are limited for
these specific risk and age groups. However, the vaccine is safe and immunogenic among
all healthy children aged 24–59 months. Also, immunogenicity data are available regard-
ing use of another pneumococcal conjugate vaccine among Apache, Navajo, and Alaska
Native children (101 ), and efficacy data for children aged 23 months probably are
relevant for healthy children aged 24–59 months (Strength of Evidence: B).
PPV23 is licensed for use among children aged 2 years who are at high risk for
pneumococcal infections (e.g., those with SCD or HIV infection). However, the conjugate
vaccine has advantages over PPV23, which include induction of immune system memory
(possibly resulting in longer duration of protection), reduction in carriage, probable higher
efficacy against serotypes causing most invasive disease, and probable effectiveness
against noninvasive syndromes (e.g., nonbacteremic pneumonia and AOM). If pneumo-
coccal vaccine is to be used among healthy children aged 24–59 months, ACIP recom-
mends that PCV7 be used.
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Vaccination Schedules. ACIP recommends that one dose of PCV7 be considered for
Alaska Native and American Indian children aged 24–59 months. Previously, ACIP rec-
ommended PPV23 for Alaska Natives and certain American Indian populations aged
2 years (1 ). However, use of PCV7 among these children offers multiple potential ad-
vantages over PPV23 as previously discussed. In contrast, PPV23 offers potentially
broader serotype coverage. Recent studies demonstrate that only 68% and 57% of
invasive infections among Alaska Natives and American Indians in the U.S. Southwest
aged 24–59 months, respectively, were caused by serotypes included in the 7-valent
conjugate vaccine, lower proportions than among non-Alaska Native/non-American In-
dian populations (115,116 ). Therefore, vaccination program personnel and other health-
care providers might consider whether Alaska Native and American Indian children
aged 24–59 months would benefit by the additional coverage provided by the 23-valent
polysaccharide vaccine. Data are limited regarding safety and immunogenicity of PPV23
after PCV7. If additional serotype coverage is desired by parents and health-care provid-
ers, PPV23 should be administered 2 months after PCV7 (Strength of evidence: C). A
community-randomized trial to evaluate the efficacy of PCV7 among Navajo and Apache
children in preventing pneumococcal disease is underway. Future recommendations for
use of PCV7 among Alaska Native and American Indian populations might be modified on
the basis of that trial.
ACIP recommends that physicians consider administering one dose of PCV7 to their
African-American pediatric patients aged 24–59 months because of their increased risk
for pneumococcal infection. The proportion of invasive pneumococcal disease among
African-American children that is caused by PCV7 serotypes does not differ from whites
in the United States, and rates of invasive disease decline with age (ABCs/EIP Network,
unpublished data, 2000). Therefore, no additional vaccination with PPV23 is recom-
mended (Strength of evidence: B). Additionally, because of increased risk for invasive
pneumococcal disease, colonization with antibiotic-resistant pneumococcal strains, and
AOM, health-care providers should consider administering one dose of PCV7 to previ-
ously unvaccinated children aged 24–59 months who attend group day care centers.
Children Aged 5 Years and Adults Who Are At High
Risk for Pneumococcal Infection
Data are limited regarding efficacy of PCV7 among children aged 5 years and adults.
However, limited studies report that a) 5-valent pneumococcal conjugate vaccine is
immunogenic among HIV-infected children aged 2–9 years (94 ); b) PCV7 is immunogenic
among children aged 2–13 years with recurrent respiratory infections (117 ); and c) PCV7
is immunogenic among older children and adults aged 4–30 years with SCD (93 ). Admin-
istering PCV7 to older children with high-risk conditions is not contraindicated.
Studies among healthy adults aged 50 years (118 ) and among HIV-infected adults
aged 18–65 years (119 ) did not demonstrate substantially greater ELISA antibody con-
centrations after administration of 5-valent pneumococcal conjugate vaccine compared
with PPV23. Also, the proportion of invasive pneumococcal isolates covered by PCV7 is
only 50%–60% among older children and adults, in contrast with 80%–90% coverage by
PPV23 among this older group. Therefore, current data do not support a recommenda-
tion to replace PPV23 with PCV7 among older children and adults.
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Recommendations for Use of PCV7 Among Children
Previously Vaccinated with PPV23
Children aged 24–59 months who are at high risk for pneumococcal disease and who
have already received PPV23 (i.e., children with SCD, HIV infection, or who have other
immunocompromising illnesses or chronic diseases) could benefit from the immunologic
priming and T-cell–dependent immune system response induced by PCV7. Thus, among
children in these groups at high risk, sequential use of the two pneumococcal vaccines
can provide additional protection. Health-care providers should vaccinate children aged
24–59 months at high risk who have not previously received PCV7 but who have already
received PPV23 with two doses of PCV7 administered 2 months apart. Vaccination with
PCV7 should be initiated 2 months after vaccination with PPV23. Providers should be
aware that minimal safety data are available regarding this vaccine sequence.
Recommendations for Use of PPV23 Among Children
Previously Vaccinated with PCV7
Administration of PCV7 Followed by PPV23 Among Children
at High Risk for Pneumococcal Disease
Children who have completed the PCV7 vaccination series before age 2 years and
who are among risk groups for which PPV23 is already recommended should receive
one dose of PPV23 at age 2 years (2 months after the last dose of PCV7). These groups
at high risk include children with SCD, children with functional or anatomic asplenia,
children who are HIV-infected, and children who have immunocompromising or chronic
diseases (1 ) (Table 8). Although data regarding safety of PPV23 administered after PCV7
are limited, the opportunity to provide additional serotype coverage among these chil-
dren at very high risk justifies use of the vaccines sequentially. For children of Alaska
Native or American Indian descent, addition of PPV23 after PCV7 can be considered.
Revaccination with PPV23
Immunocompromised children or children with SCD or functional or anatomic asplenia
should be revaccinated with PPV23 as previously recommended (1 ) (Table 12). If the
child is aged 10 years, one revaccination should be considered 3–5 years after the
previous dose of PPV23 (1,120 ). Data are limited regarding adverse events related to a
second dose of PPV23 administered after PCV7. Health-care providers should not admin-
ister a second dose of PPV23 any earlier than 3 years after the initial dose of PPV23.
AREAS FOR FUTURE RESEARCH
With recent licensure and introduction of PCV7, close monitoring of disease trends
and long-term vaccine safety will be high priorities for public health organizations and
health-care providers. Postlicensure surveillance will be necessary to a) detect potential
changes in serotype distribution, including any increase in disease caused by serotypes
not contained in PCV7; b) follow trends in antimicrobial resistance and antibiotic use;
c) detect potential herd immunity induced by widespread use of PCV7; and d) track
vaccine-related health events.
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Areas where research is ongoing or necessary to determine the most effective use of
PCV7 include the following:
• Optimal vaccination schedule for older children at high risk. Further studies are
needed to identify optimal vaccination schedules for PCV7 and PPV23 among
children aged 2 years who are at high risk for infection, including children with
SCD, HIV infection, and other chronic diseases or immunocompromising
conditions, particularly children who have received a bone marrow transplant.
Research is critical regarding optimal scheduling of vaccination with PCV7 among
children who have already received PPV23 and revaccination with PPV23 after
vaccination with PCV7.
• Combined vaccines including PCV7 and other routine vaccines for infants.
Reducing the number of required separate injections would improve the infant
vaccination schedule. Additional research is needed to evaluate safety and
immunogenicity of PCV7 when administered in combination with other antigens.
• Studies of safety, immunogenicity, and efficacy among adults at high risk for
pneumococcal infection. Additional studies are needed to evaluate potential use of
PCV7 among adults at increased risk for pneumococcal infection. Benefits and risks
involved with using a 7-, 9-, 11-, or 15-valent pneumococcal conjugate vaccine in
place of or in addition to PPV23 warrant further investigation. Rationale for
additional study of a combined or sequential regimen includes potential benefits of
conjugate pneumococcal vaccines (e.g., induction of immunologic memory with
increased duration of protection, reduction of nasopharyngeal carriage of pneumococci,
and potential impact on nonbacteremic pneumonia) along with the benefit of broader
serotype coverage provided by PPV23.
• Duration of protection. For persons of all age groups, duration of protection after
vaccination with PCV7 is unknown. Investigation of potential need for revaccination
with PCV7 or PPV23 after primary vaccination is warranted.
• Identifying and defining immune system correlates of protection. Type-specific
antibody concentration necessary to confer protection against pneumococcal
infection is unknown. Researchers are attempting to determine and standardize
the level of antibody, as measured by ELISA, that provides serotype-specific
protection against pneumococcal disease. Functional tests of induced immune
system response (e.g., opsonophagocytosis) are also being evaluated. A
determination of immunologic markers that best correlate with clinical protection
is needed. Validated immune system correlates of protection will accelerate
evaluation and licensure of new vaccines against pneumococcal infection.
• Alternative pneumococcal vaccines. Research is ongoing regarding development
of alternative pneumococcal vaccines. Investigators are evaluating possible roles
of conserved pneumococcal proteins (e.g., pneumolysin, surface protein A, or
surface adhesion A) as antigens that have potential to provide broad protection
against disease caused by all pneumococcal serotypes (121 ). Use of other
peptides or pneumococcal proteins as carriers in conjugate vaccines is also being
studied. Additionally, alternative routes of delivery including intranasally and
orally administered vaccines are under investigation (122,123 ).
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answer will instruct you to “Indicate all that apply.”
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Goals and Objectives
This MMWR  provides guidance for preventing pneumococcal disease among infants and young children in the
United States. These recommendations were developed by the Advisory Committee on Immunization Practices
(ACIP). The goals of this report are to provide ACIP’s recommendations regarding the 7-valent pneumococcal
polysaccharide-protein conjugate vaccine and to update previous ACIP recommendations regarding use of 23-
valent pneumococcal polysaccharide vaccine among children. Upon completion of this educational activity, the
reader should be able to a) describe the burden of pneumococcal disease among infants and young children in
the United States; b) describe the characteristics of the newly licensed 7-valent pneumococcal conjugate
vaccine; c) identify groups of infants and children for whom the 7-valent pneumococcal polysaccharide-protein
conjugate vaccine is recommended; d) recognize contraindications to the administration of pneumococcal
conjugate vaccine; and e) identify children for whom vaccination with 23-valent pneumococcal polysaccharide
is appropriate.
To receive continuing education credit, please answer all of the following questions.
1. Which of the following statements is true concerning the burden of pneumococcal disease among
children in the United States?
A. Infection with Streptococcus pneumoniae  is second only to Haemophilus influenzae  type b (Hib) as
a cause of bacterial meningitis among children.
B. The highest rate of invasive pneumococcal disease among any age group is among children aged 24–
35 months.
C. The most common manifestation of invasive pneumococcal disease among young children is
bacteremia without a known site of infection.
D. Invasive pneumococcal disease is responsible for >1,000 deaths/year among children aged <5 years.
E. Pneumococci is found among <10% of middle ear aspirates in children with acute otitis media.
2. Which of the following groups of children have not been found to be at increased risk for invasive
pneumococcal disease?
A. Children of Alaska Native descent.
B. Children of African-American descent.
C. Children infected with human immunodeficiency virus.
D. Children with sickle cell disease.
E. Children with asthma who are not on high doses of steroids.
3. Which of the following is an advantage of using pneumococcal conjugate vaccine?
A. Pneumococcal conjugate vaccine stimulates a T-dependent immune system response.
B. Pneumococcal conjugate vaccine causes a primary response in infants.
C. Reexposure to pneumococcal conjugate vaccine results in a booster response.
D. Pneumococcal conjugate vaccine reduces carriage of pneumococci covered by the vaccine.
E. All the above are advantages of pneumococcal conjugate vaccine.
4. How many types of pneumococcal capsular polysaccharide are included in the newly licensed
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5. Which type of pneumococcal disease is pneumococcal conjugate vaccine effective in preventing?
A. Acute otitis media.
B. Bacteremia.
C. Pneumonia.
D. Pneumococcal conjugate vaccine is effective in preventing all the above types of pneumococcal
disease.
6. What is the routine schedule for administering pneumococcal conjugate vaccine among infants?
A. A total of four doses administered at ages 2, 4, 6, and 12–15 months.
B. A total of three doses administered at ages 2, 4, and 12–15 months.
C. A total of three doses administered at birth and ages 2 and 6 months.
D. A total of two doses administered at ages 12 months and 4 years.
E. One dose administered at age 12–15 months.
7. Which of the following conditions is a valid contraindication or precaution for use of pneumococcal
conjugate vaccine?
A. Infection with human immunodeficiency virus.
B. Known hypersensitivity to a component of the vaccine.
C. Recent administration of antibody-containing blood product (e.g., whole blood or immunoglobulin).
D. Current administration of antibiotics.
E. All of the above are valid contraindications or precautions for use of pneumococcal conjugate vaccine.
8. For which group of children is routine vaccination with pneumococcal conjugate vaccine not
recommended?
A. Children aged <12 months.
B. Children aged <23 months.
C. Children aged 24–59 months infected with human immunodeficiency virus.
D. Healthy children aged 5 years.
E. Routine vaccination with pneumococcal conjugate vaccine is not recommended for any of the above
groups of children.
9. What pneumococcal vaccination schedule is recommended for previously unvaccinated children aged
24–59 months who are immunocompromised or who have chronic illness that places them at high risk for
invasive pneumococcal disease?
A. One dose of pneumococcal conjugate vaccine.
B. A total of two doses of pneumococcal conjugate vaccine administered 2 months apart.
C. A total of three doses of pneumococcal conjugate vaccine administered 2 months apart.
D. One dose of pneumococcal polysaccharide vaccine only.
E. A total of two doses of pneumococcal conjugate vaccine administered 2 months apart, followed by
one dose of pneumococcal polysaccharide vaccine administered 2 months after the second dose of
pneumococcal conjugate vaccine.
10. ACIP does not recommend the 23-valent polysaccharide vaccine for which of the following children?
A. Children aged 3 years who do not have spleens.
B. Children aged 4 years who attend group day care.
C. Children aged 4 years who are infected with human immunodeficiency virus.
D. Children aged 3 years who have leukemia.
E. Children aged 2 years who have nephrotic syndrome.
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11. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
12. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.




13. I plan to use these recommendations as the basis for . . . (Indicate all that apply. )
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.







15. How much time did you spend reading this report and completing the exam?
A. Less than 1 hour.
B. 1–1.5 hours.
C. 1.6–2 hours.
D. More than 2 hours.
16. After reading this report, I am confident I can describe the burden of pneumococcal disease among infants
and young children in the United States.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can identify groups of infants and children for whom the 7-valent
pneumococcal polysaccharide-protein conjugate vaccine is recommended.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can identify children for whom vaccination with 23-valent
pneumococcal polysaccharide is appropriate.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. The tables and figures are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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23. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR  cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR  subscription.
F. Other.
Correct answers for questions 1–10:
1. C; 2. E; 3. E; 4. C; 5. D; 6. A; 7. B; 8. D; 9. E; 10. B.
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